These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 12941773

  • 1. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
    Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU.
    Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
    [Abstract] [Full Text] [Related]

  • 2. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
    Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK.
    Biochem Biophys Res Commun; 2002 Aug 16; 296(2):293-9. PubMed ID: 12163016
    [Abstract] [Full Text] [Related]

  • 3. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.
    Larsen PJ, Jensen PB, Sørensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K.
    Diabetes; 2003 Sep 16; 52(9):2249-59. PubMed ID: 12941763
    [Abstract] [Full Text] [Related]

  • 4. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM.
    Biochem Biophys Res Commun; 2005 Oct 28; 336(3):747-53. PubMed ID: 16157299
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
    Desouza CV, Murthy SN, Diez J, Dunne B, Matta AS, Fonseca VA, McNamara DB.
    J Cardiovasc Pharmacol Ther; 2003 Dec 28; 8(4):297-305. PubMed ID: 14740079
    [Abstract] [Full Text] [Related]

  • 6. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
    Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T.
    Diabetes; 1998 Dec 28; 47(12):1841-7. PubMed ID: 9836514
    [Abstract] [Full Text] [Related]

  • 7. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
    Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, Lee HC, Cha BS.
    Metabolism; 2007 May 28; 56(5):676-85. PubMed ID: 17445544
    [Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
    Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW.
    Endocrinology; 2006 Sep 28; 147(9):4252-62. PubMed ID: 16728496
    [Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
    Liang F, Wang F, Zhang S, Gardner DG.
    Endocrinology; 2003 Sep 28; 144(9):4187-94. PubMed ID: 12933694
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
    Singh Ahuja H, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJ.
    Mol Pharmacol; 2001 Apr 28; 59(4):765-73. PubMed ID: 11259621
    [Abstract] [Full Text] [Related]

  • 11. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
    Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S.
    Am J Physiol Endocrinol Metab; 2004 Apr 28; 286(4):E560-7. PubMed ID: 14625208
    [Abstract] [Full Text] [Related]

  • 12. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS.
    Diabetes Metab Res Rev; 2003 Apr 28; 19(6):487-93. PubMed ID: 14648808
    [Abstract] [Full Text] [Related]

  • 13. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
    Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye JM, Sauerberg P, Wassermann K.
    Am J Physiol Endocrinol Metab; 2003 Apr 28; 284(4):E841-54. PubMed ID: 12475752
    [Abstract] [Full Text] [Related]

  • 14. Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
    Fernandes-Santos C, Evangelista Carneiro R, de Souza Mendonca L, Barbosa Aguila M, Mandarim-de-Lacerda CA.
    Pancreas; 2009 Apr 28; 38(3):e80-6. PubMed ID: 19214135
    [Abstract] [Full Text] [Related]

  • 15. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D, Medicherla S, Neogi P, Gowri M, Cheng J, Gross C, Sharma SD, Reaven GM, Nag B.
    Metabolism; 2003 Aug 28; 52(8):1012-8. PubMed ID: 12898466
    [Abstract] [Full Text] [Related]

  • 16. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
    Chaput E, Saladin R, Silvestre M, Edgar AD.
    Biochem Biophys Res Commun; 2000 May 10; 271(2):445-50. PubMed ID: 10799317
    [Abstract] [Full Text] [Related]

  • 17. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.
    Mol Endocrinol; 2005 Jun 10; 19(6):1593-605. PubMed ID: 15831517
    [Abstract] [Full Text] [Related]

  • 18. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
    Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL.
    Arterioscler Thromb Vasc Biol; 2003 Jan 01; 23(1):45-51. PubMed ID: 12524223
    [Abstract] [Full Text] [Related]

  • 19. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
    Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P.
    Int J Obes (Lond); 2007 Aug 01; 31(8):1302-10. PubMed ID: 17310221
    [Abstract] [Full Text] [Related]

  • 20. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.
    Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J.
    J Biol Chem; 1997 Nov 07; 272(45):28210-7. PubMed ID: 9353271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.